Research review priorities
Supplement research priorities
These are research priorities, not recommendations. We selected decisions where public interest, plausible benefit, evidence maturity, and safety stakes make a careful synthesis especially useful.
- priority dossiers
- 148
- claim-level questions
- 444
- study extraction underway
- 148
01 / PRIORITY
How priorities were selected
Priority reflects relevance to healthy aging, frequency of real-world use, maturity of human evidence, the cost of a wrong decision, and the need to separate a valid narrow use from broader marketing claims. It does not rank efficacy or imply that everyone should take the product.
02 / EXTRACTION
What happens next
For every question, we screen the PubMed candidate set, connect multiple publications from the same trial, extract population, dose, comparator, duration, outcomes, harms, and funding, then synthesize supportive, mixed, negative, and safety findings together.
Only screened studies enter audited study and participant totals. Search-result counts and the papers listed here as questions never become evidence by themselves.D-chiro-inositol
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
D-chiro-inositol has a possible ovulation signal within a heterogeneous literature, but subtype-specific efficacy and safe dosing remain uncertain.
Questions being reviewed
- Does D-chiro-inositol improve ovulation, live birth, and patient-important PCOS outcomes?
- Is D-chiro-inositol monotherapy or a specific myo-to-DCI ratio supported by direct comparisons?
- What dose, duration, ovarian, metabolic, pregnancy, medicine, and fertility-care limits apply?
Ubiquinone CoQ10
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
CoQ10 may reduce mortality and hospitalization as adjunctive heart-failure therapy, but the evidence is trial-concentrated, bias-prone, and not a general wellness claim.
Questions being reviewed
- Does ubiquinone CoQ10 reduce patient-important outcomes when added to guideline-directed heart-failure care?
- Which statin-muscle, fatigue, migraine, fertility, or general-aging claims have independent outcome evidence?
- What formulation, dose, duration, anticoagulant, blood-pressure, diabetes, and clinician-supervision limits apply?
Ubiquinol CoQ10
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Small pharmacokinetic studies do not show a universal ubiquinol absorption advantage and cannot establish superior clinical outcomes.
Questions being reviewed
- Is ubiquinol consistently more bioavailable than well-formulated ubiquinone across ages and products?
- Does any exposure difference produce superior symptoms, function, hospitalization, or survival outcomes?
- What formulation, dose, duration, anticoagulant, blood-pressure, diabetes, and product-quality limits apply?
L-citrulline
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
Placebo-controlled synthesis does not support improved aerobic performance, while blood-pressure findings are inconsistent and based on very small trials.
Questions being reviewed
- Does L-citrulline improve time trial, endurance, oxygen uptake, or perceived exertion?
- Does it meaningfully lower brachial or central blood pressure in people with hypertension?
- What dose, timing, gastrointestinal, hypotension, nitrate, PDE5-drug, and kidney limits apply?
Citrulline malate
- Review stage
- Extracting studies
- audited research papers
- 1
Why this is a research priority
A current GRADE review found only a very small, context-dependent performance signal with low-to-very-low certainty and no established protocol.
Questions being reviewed
- Which acute or chronic exercise outcomes improve beyond a trivial magnitude?
- How do citrulline-to-malate ratio, verified ingredient content, dose, and timing change results?
- What gastrointestinal, blood-pressure, nitrate, PDE5-drug, kidney, and competition-quality limits apply?
03 / SOURCES
Research standards
The review begins with federal evidence summaries and PubMed records, then moves to trial-level extraction. Product claims or another publisher’s evidence grade are not copied into the ledger.